Aarti Pharmalabs Limited — Others, 12-08-2025: Appointment

Aarti Pharmalabs' board approved Q1 FY26 financial results, showing standalone revenue of ₹375.31 Cr and net profit of ₹51.22 Cr. Consolidated revenue was ₹386.19 Cr with a net profit of ₹49.50 Cr. Consolidated figures are not directly comparable to previous periods due to Ganesh Polychem becoming a joint venture from April 1, 2025. The board also approved the re-appointment of Ms. Rupal Vora as an Independent Director and proposed extending the company's stock option scheme to subsidiary employees, pending shareholder approval. This reflects ongoing governance and compensation strategy.